Clinical Trials Search Results

Search for

Showing 1-5 of 5

Sorted By:

A-Z
Z-A

Previous Next

A031704: D-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE] (Location: Aberdeen) (temporarily closed to enrollment effective 15-May-2024)
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body.
A031704: D-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE] (Location: Sioux Falls) (Temporarily closed to enrollment effective 15-May-2024)
This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body.
D910L00001 (MERMAID-1): A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected stage II-III NSCLC who are MRD+ post surgery
EA4181: A Randomized 3-Arm Phase II Study Comparing Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma (enrollment temporarily suspended 30-Sep-2022)
3 chemos: bendamustine, rituximab, high dose cytarabine & acalabrutinib & studies how well they work in treating patients w/ newly diagnosed mantle cell lymphoma
GOG 3083_XPORT-EC-042: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Ph 3, Rand,Placebo-Controlled,Double-Blind,Multicenter Trial ofSelinexor in Maint.Therapy After Systemic Therapy for Ptsw/p53 Wild-Type, Adv or Recurrent Endometrial Carcinoma

Previous Next